The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: The secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status.
Clinical Colorectal Cancer.
Times cited: 27
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
Journal of Clinical Oncology.
Times cited: 228